Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Newborn Hearing Screening - An Implementation Analysis

T. Kostlivý, P. Škopek, P. Klail, H. Laierová, A. Skálová, B. Gál, R. Kučera, V. Šimánek, D. Slouka

. 2024 ; 38 (4) : 1939-1946. [pub] -

Language English Country Greece

Document type Journal Article

BACKGROUND/AIM: Hearing impairment affects a small but significant percentage of newborns (0.1-0.4%). Newborn hearing screening (NHS) is recommended for early detection and treatment. The implementation of NHS can vary among countries. In this study, we present the methodology, organization, and technical requirements of NHS. This study analyzed results from a tertiary hospital, identified issues, and proposed solutions. PATIENTS AND METHODS: In the studied region, there are five maternity hospitals and a perinatal intensive care center and in 2020, there were 5,864 live births. Screening is performed at three levels. The first screening is conducted on the 2nd-3rd day of a newborn's life in a maternity hospital, the first rescreening on the 3rd-6th week at a relevant ENT department, and the second rescreening on the 3rd-6th month of life at the regional screening center where the central database is also held. RESULTS: In the studied region, 5,793 out of 5,864 (98.79%) newborns received NHS in 2020. Of these, 120 (2.07%) were tested positive on their first screening. Ninety-four patients (78.3%) of those attended the ENT department for a first rescreening. Thirty-four patients (0.59% of total) were tested positive again and referred to the regional screening center. Out of the 27 patients who attended the second rescreening, four (0.07% of the total) were ultimately diagnosed with hearing impairment. CONCLUSION: Our study found that newborn hearing screening (NHS) in our region achieved a high compliance rate of 98.8% for initial screenings in 2020. However, challenges remain in the rescreening process due to data management issues, inter-regional cooperation, and public awareness. The recent implementation of mandatory screenings, updated guidelines, and a centralized database is expected to enhance the effectiveness of NHS. Further research is needed to evaluate these improvements.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013336
003      
CZ-PrNML
005      
20250129143914.0
007      
ta
008      
240725s2024 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.13650 $2 doi
035    __
$a (PubMed)38936904
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kostlivý, Tomáš $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Newborn Hearing Screening - An Implementation Analysis / $c T. Kostlivý, P. Škopek, P. Klail, H. Laierová, A. Skálová, B. Gál, R. Kučera, V. Šimánek, D. Slouka
520    9_
$a BACKGROUND/AIM: Hearing impairment affects a small but significant percentage of newborns (0.1-0.4%). Newborn hearing screening (NHS) is recommended for early detection and treatment. The implementation of NHS can vary among countries. In this study, we present the methodology, organization, and technical requirements of NHS. This study analyzed results from a tertiary hospital, identified issues, and proposed solutions. PATIENTS AND METHODS: In the studied region, there are five maternity hospitals and a perinatal intensive care center and in 2020, there were 5,864 live births. Screening is performed at three levels. The first screening is conducted on the 2nd-3rd day of a newborn's life in a maternity hospital, the first rescreening on the 3rd-6th week at a relevant ENT department, and the second rescreening on the 3rd-6th month of life at the regional screening center where the central database is also held. RESULTS: In the studied region, 5,793 out of 5,864 (98.79%) newborns received NHS in 2020. Of these, 120 (2.07%) were tested positive on their first screening. Ninety-four patients (78.3%) of those attended the ENT department for a first rescreening. Thirty-four patients (0.59% of total) were tested positive again and referred to the regional screening center. Out of the 27 patients who attended the second rescreening, four (0.07% of the total) were ultimately diagnosed with hearing impairment. CONCLUSION: Our study found that newborn hearing screening (NHS) in our region achieved a high compliance rate of 98.8% for initial screenings in 2020. However, challenges remain in the rescreening process due to data management issues, inter-regional cooperation, and public awareness. The recent implementation of mandatory screenings, updated guidelines, and a centralized database is expected to enhance the effectiveness of NHS. Further research is needed to evaluate these improvements.
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    12
$a novorozenecký screening $x metody $7 D015997
650    12
$a sluchové testy $x metody $7 D006320
650    12
$a nedoslýchavost $x diagnóza $x epidemiologie $7 D034381
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
655    _2
$a časopisecké články $7 D016428
700    1_
$a Škopek, Petr $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Klail, Pavel, $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $d 1995- $7 xx0328572
700    1_
$a Laierová, Hana $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Skálová, Alena $u Department of Pathology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Gál, Břetislav $u Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kučera, Radek $u Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Šimánek, Václav $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Slouka, David $u Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; slouka@fnplzen.cz
773    0_
$w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 38, č. 4 (2024), s. 1939-1946
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38936904 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20250129143909 $b ABA008
999    __
$a ok $b bmc $g 2143258 $s 1225202
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 4 $d 1939-1946 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...